arrow
H

Heinz Gisslinger

Medical University of Vienna
H指数:76
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Thromboembolism and bleeding in newly diagnosed Multiple Myeloma – Rates, risk profile and patterns of thromboprophylaxis

血栓栓塞和出血在 newly diagnosed Multiple Myeloma 中的发生率、风险特征及抗血栓预防模式

2025-08-260
OAAI
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera

中性粒细胞与淋巴细胞比值作为JAK2V617F抑制和事件-free生存的替代指标在真性红细胞增多症中的应用

2025-08-060
OAAI
Optimizing Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma: Impact of Dose Modifications on Adverse Events and Hematologic Response in a Real-World Retrospective Study

优化Belantamab Mafodotin在复发或难治性多发性骨髓瘤中的应用:一项真实世界回顾性研究中剂量调整对不良事件和血液学反应的影响

2025-07-290
OA
A Clinically Applicable Model Using Blood Counts to Support the Diagnosis of Prefibrotic Myelofibrosis Versus Essential Thrombocythemia

一种临床适用模型:使用血细胞计数支持前纤维化骨髓纤维化与原发性血小板增多症的诊断鉴别

2025-07-260
PRE
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms
2023-03-094
OA
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 x 109/L to < 100 x 109/L) at baseline: the final analysis of EXPAND
2022-09-109
OAAI
PD-L1 overexpression correlates with JAK2-V617F mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms
2022-01-2114
OAAI
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
LEUKEMIA
IF13.4
2021-05-2039
OAAI
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
2020-10-205
OAAI
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
LEUKEMIA
IF13.4
2020-08-078
OAAI
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
2020-03-01232
OAAI
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases
2019-11-2957
OAAI